skip to content

Department of Pharmacology

 
Author(s): 
Rubio, A, Garland, GD, Sfakianos, A, Harvey, RF, Willis, AE
Abstract: 

In tumourigenesis, oncogenes or dysregulated tumour suppressor genes alter the canonical translation machinery leading to a reprogramming of the translatome that, in turn, promotes the translation of selected mRNAs encoding proteins involved in proliferation and metastasis. It is therefore unsurprising that abnormal expression levels and activities of eukaryotic initiation factors (eIFs), elongation factors (eEFs) or termination factors (eRFs) are associated with poor outcome for patients with a wide range of cancers. In this review we discuss how RNA binding proteins (RBPs) within the canonical translation factor machinery are dysregulated in cancers and how targeting such proteins is leading to new therapeutic avenues.

Publication ID: 
1382620
Published date: 
November 2022
Publication source: 
pubmed
Publication type: 
Journal articles
Journal name: 
Semin Cancer Biol
Publication volume: 
86
Publisher: 
Parent title: 
Edition: 
Publication number: